Zevra Therapeutics, Inc. ZVRA OLPRUVA — Revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
On December 27, 2022, the FDA approved OLPRUVA (sodium phenylbutyrate), a prescription medicine used along with certain therapy, including changes in diet, for the chronic management of adults and children with certain UCDs. For the three and six months ended June 30, 2026, sales of OLPRUVA were $0.2 million and $0.5 million, respectively. For the three and six months ended June 30, 2025, sales of OLPRUVA were $0.3 million and $0.4 million, respectively.
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s OLPRUVA — revenue, net?
- Zevra Therapeutics, Inc. (ZVRA) reported OLPRUVA — revenue, net of $200K in Q2 2026.
- How has Zevra Therapeutics, Inc.'s OLPRUVA — revenue, net changed year-over-year?
- Zevra Therapeutics, Inc.'s OLPRUVA — revenue, net decreased by 33.3% year-over-year, from $300K to $200K.
- What does OLPRUVA — revenue, net mean?
- This metric represents the total net sales generated from the commercialization of the OLPRUVA product line after accounting for returns, allowances, and rebates. It serves as a primary indicator of the product's market adoption and commercial traction within the rare disease therapeutic space. Tracking this revenue stream helps investors evaluate the company's ability to successfully execute its commercial strategy for specialized orphan drug assets.
Ask your AI about Zevra Therapeutics, Inc.'s olpruva — revenue, net.
Connect your AI assistant and compare segments, right in your chat.
